Skip to main content
Top
Published in: Journal of Gastroenterology 9/2010

01-09-2010 | Original Article—Alimentary Tract

Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients

Authors: Makoto Naganuma, Hitoshi Ichikawa, Nagamu Inoue, Taku Kobayashi, Susumu Okamoto, Tadakazu Hisamatsu, Takanori Kanai, Haruhiko Ogata, Yasushi Iwao, Toshifumi Hibi

Published in: Journal of Gastroenterology | Issue 9/2010

Login to get access

Abstract

Aim

Clinical symptoms are the most important factors used by physicians to evaluate the severity and extent of ulcerative colitis (UC). In this context, colonoscopy is also a useful diagnostic tool. We have recently developed an endoscopic activity index (EAI) to assess the severity of UC. Here, we assess the correlations among the EAI, other endoscopic indices, and clinical scores. The usefulness of the EAI for choosing treatment options, such as intravenous corticosteroid or cyclosporine A (CsA), in severe UC patients was also evaluated.

Methods

Clinical symptoms and endoscopic finding were evaluated in 396 patients with UC (454 colonoscopies). The EAI was scored using the following six items: ulcer size, ulcer depth, redness, bleeding, edema, and mucus exudates. The patients were also scored using Matts’ grade, Rachmilewitz’s endoscopic index, and the Lichtiger index.

Results

Our results showed that (1) the EAI scores were closely correlated with those of the Lichtiger index, Matts’ grade, and Rachmilewitz’s endoscopic index; (2) the EAI scores significantly decreased in patients who responded to treatment, while Matts’ grade did not change in some responders treated with intravenous CsA and steroid; (3) patients with a higher EAI (14–16) tended to be refractory to corticosteroid therapy (responders 19%) compared to CsA (77%), while steroid treatment was effective in 58% of patients with EAI scores of 11–13.

Conclusions

The EAI is equivalent to other endoscopic indices and relatively more useful in choosing a treatment for patients with severe UC.
Literature
1.
go back to reference Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J. 1955;2:104–8.CrossRef Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J. 1955;2:104–8.CrossRef
2.
go back to reference Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J. 1962;2:441–3.CrossRefPubMed Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J. 1962;2:441–3.CrossRefPubMed
3.
go back to reference Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.CrossRefPubMed Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.CrossRefPubMed
4.
go back to reference D’Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al. Intravenous cyclosporin versus intravenous glucocorticosteroids as a single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323–9.CrossRefPubMed D’Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al. Intravenous cyclosporin versus intravenous glucocorticosteroids as a single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323–9.CrossRefPubMed
5.
go back to reference Svavoni F, Bonassi U, Bagnolo F. Effectiveness of cyclosporine in the treatment of refractory ulcerative colitis. Gastroenterology. 1998;114:A1096.CrossRef Svavoni F, Bonassi U, Bagnolo F. Effectiveness of cyclosporine in the treatment of refractory ulcerative colitis. Gastroenterology. 1998;114:A1096.CrossRef
6.
go back to reference Van Assche G, D’Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized double-blind comparison of 4 mg/kg/day versus 2 mg/kg/day intravenous cyclosporin in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.CrossRefPubMed Van Assche G, D’Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized double-blind comparison of 4 mg/kg/day versus 2 mg/kg/day intravenous cyclosporin in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.CrossRefPubMed
7.
go back to reference Moskovitz D, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of colectomy during long term follow up after cyclosporin-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760–5.CrossRefPubMed Moskovitz D, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of colectomy during long term follow up after cyclosporin-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760–5.CrossRefPubMed
8.
go back to reference Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11.CrossRefPubMed Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–11.CrossRefPubMed
9.
go back to reference Van Assche G, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol. 2008;14:5508–11.CrossRefPubMed Van Assche G, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol. 2008;14:5508–11.CrossRefPubMed
10.
go back to reference Rachmilwitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J. 1989;298:82–6.CrossRef Rachmilwitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J. 1989;298:82–6.CrossRef
11.
go back to reference Matts SGF. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393–407.PubMed Matts SGF. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393–407.PubMed
12.
go back to reference Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, et al. Granulocytopheresis is useful as an alterative therapy for steroid refractory and dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251–7.CrossRefPubMed Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, et al. Granulocytopheresis is useful as an alterative therapy for steroid refractory and dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251–7.CrossRefPubMed
13.
go back to reference D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.CrossRefPubMed D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86.CrossRefPubMed
14.
go back to reference Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987;317:1625–9.CrossRefPubMed Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987;317:1625–9.CrossRefPubMed
15.
go back to reference Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894–8.PubMed Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894–8.PubMed
16.
go back to reference Ando T, Nishio Y, Watanabe O, Takahashi H, Maeda O, Ishiguro K, et al. Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis. World J Gastroenterol. 2008;14:2133–8.CrossRefPubMed Ando T, Nishio Y, Watanabe O, Takahashi H, Maeda O, Ishiguro K, et al. Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis. World J Gastroenterol. 2008;14:2133–8.CrossRefPubMed
17.
go back to reference Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2008;103:637–42.CrossRefPubMed Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2008;103:637–42.CrossRefPubMed
Metadata
Title
Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients
Authors
Makoto Naganuma
Hitoshi Ichikawa
Nagamu Inoue
Taku Kobayashi
Susumu Okamoto
Tadakazu Hisamatsu
Takanori Kanai
Haruhiko Ogata
Yasushi Iwao
Toshifumi Hibi
Publication date
01-09-2010
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 9/2010
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-010-0244-2

Other articles of this Issue 9/2010

Journal of Gastroenterology 9/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.